216 related articles for article (PubMed ID: 27813059)
21. Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis.
Tie Y; Yang H; Zhao R; Zheng H; Yang D; Zhao J; Liu M
Drug Des Devel Ther; 2019; 13():523-538. PubMed ID: 30787594
[TBL] [Abstract][Full Text] [Related]
24. Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy.
Lee YJ; Kim HT; Won CH; Chang SE; Lee MW; Choi JH; Lee WJ
J Korean Med Sci; 2019 Jul; 34(26):e186. PubMed ID: 31269545
[TBL] [Abstract][Full Text] [Related]
25. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab: a review in advanced squamous non-small cell lung cancer.
Keating GM
Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
[TBL] [Abstract][Full Text] [Related]
28. The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
Wu Y; Shi H; Jiang M; Qiu M; Jia K; Cao T; Shang Y; Shi L; Jiang K; Wu H
Int J Cancer; 2017 Dec; 141(12):2562-2570. PubMed ID: 28833119
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies.
Sun C; Chen H; Wang Y; Zheng C
Hematology; 2023 Dec; 28(1):2181749. PubMed ID: 36892260
[TBL] [Abstract][Full Text] [Related]
30. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
Abdel-Rahman O; ElHalawani H; Fouad M
Future Oncol; 2015; 11(17):2471-84. PubMed ID: 26274495
[TBL] [Abstract][Full Text] [Related]
31. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab for the treatment of cancer.
Gunturi A; McDermott DF
Expert Opin Investig Drugs; 2015 Feb; 24(2):253-60. PubMed ID: 25494679
[TBL] [Abstract][Full Text] [Related]
33. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
Dada R
Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
[TBL] [Abstract][Full Text] [Related]
34. PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis.
Lin Z; Chen X; Li Z; Luo Y; Fang Z; Xu B; Han M
PLoS One; 2016; 11(8):e0160485. PubMed ID: 27483468
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab.
Fulchiero E; Jimeno A
Drugs Today (Barc); 2014 Dec; 50(12):791-802. PubMed ID: 25588084
[TBL] [Abstract][Full Text] [Related]
36. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
37. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study.
Yamazaki N; Kiyohara Y; Uhara H; Uehara J; Fujimoto M; Takenouchi T; Otsuka M; Uchi H; Ihn H; Minami H
Cancer Sci; 2017 Jun; 108(6):1223-1230. PubMed ID: 28342215
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
D'Angelo SP; Larkin J; Sosman JA; Lebbé C; Brady B; Neyns B; Schmidt H; Hassel JC; Hodi FS; Lorigan P; Savage KJ; Miller WH; Mohr P; Marquez-Rodas I; Charles J; Kaatz M; Sznol M; Weber JS; Shoushtari AN; Ruisi M; Jiang J; Wolchok JD
J Clin Oncol; 2017 Jan; 35(2):226-235. PubMed ID: 28056206
[TBL] [Abstract][Full Text] [Related]
40. The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis.
Su Q; Zhang XC; Wang DY; Zhang HR; Zhu C; Hou YL; Liu JL; Gao ZH
Int Immunopharmacol; 2018 Jun; 59():328-338. PubMed ID: 29679857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
